In last trading session, Cognition Therapeutics Inc (NASDAQ:CGTX) saw 0.77 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $0.71 trading at $0.07 or 10.59% at ring of the bell on the day assigns it a market valuation of $28.49M. That closing price of CGTX’s stock is at a discount of -315.49% from its 52-week high price of $2.95 and is indicating a premium of 23.94% from its 52-week low price of $0.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.73 million shares which gives us an average trading volume of 921.66K if we extend that period to 3-months.
For Cognition Therapeutics Inc (CGTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Upright in the green during last session for gaining 10.59%, in the last five days CGTX remained trading in the green while hitting it’s week-highest on Friday, 08/16/24 when the stock touched $0.71 price level, adding 3.35% to its value on the day. Cognition Therapeutics Inc’s shares saw a change of -61.62% in year-to-date performance and have moved 29.73% in past 5-day. Cognition Therapeutics Inc (NASDAQ:CGTX) showed a performance of -63.40% in past 30-days. Number of shares sold short was 1.77 million shares which calculate 0.89 days to cover the short interests.
Cognition Therapeutics Inc (CGTX) estimates and forecasts
Statistics highlight that Cognition Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -64.14% of value to its shares in past 6 months, showing an annual growth rate of -6.98% while that of industry is 17.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -21.09% during past 5 years.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Insiders are in possession of 0.56% of company’s total shares while institution are holding 28.31 percent of that, with stock having share float percentage of 28.47%. Investors also watch the number of corporate investors in a company very closely, which is 28.31% institutions for Cognition Therapeutics Inc that are currently holding shares of the company. AIGH CAPITAL MANAGEMENT LLC is the top institutional holder at CGTX for having 1.9 million shares of worth $3.45 million. And as of 2024-03-31, it was holding 5.624 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.92 million shares on 2024-03-31. The number of shares represents firm’s hold over 2.7321 of outstanding shares, having a total worth of $1.68 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 689.15 shares of worth $0.49 million or 1.72% of the total outstanding shares. The later fund manager was in possession of 196.54 shares on Mar 31, 2024 , making its stake of worth around $0.14 million in the company or a holder of 0.49% of company’s stock.
